archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CSL Limited and their involvement in clinical trials.
    tested extensively in the laboratory and in animals Clinical trials are carefully supervised monitored and documented The applicable regulatory authority must grant approval to conduct testing in humans and clinical trials are overseen by an independent review body How are clinical trials conducted CSL conducts clinical trials in accordance with the current Guideline for Good Clinical Practice GCP of the International Conference on Harmonisation ICH GCP is an international ethical and scientific quality standard for designing conducting and reporting studies that involve the participation of human subjects Compliance with this standard provides public assurance that the rights safety and well being of study subjects are protected and that the clinical trial data are credible Compliance with this standard also ensures that CSL conducts clinical trials consistent with the principles that have originated in the Declaration of Helsinki Current Studies All Bleeding Disorders Critical Care Immunoglobulins Pulmonary Therapeutic Proteins Vaccines Wound Healing Condition Additional Trial Information Hemophilia A Study of Biostate for Treatment of Children with Hemophilia A Complicated by Antibody Development Learn More Hemophilia A Study of a Plasma Derived von Willebrand Factor Factor VIII Concentrate vWF FVIII Biostate in Subjects with Hemophilia A Learn More Hemophilia B A Safety Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin rIX FP in Children With Hemophilia B Learn More Hemophilia B A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin rIX FP in Patients With Hemophilia B Learn More Hereditary Angioedema HAE Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Learn More Page 2 of 3 First Last Trial Phases Following a positive outcome in preclinical testing the sponsoring organisation usually a drug manufacturer will seek approval to conduct clinical trials Once approval has been granted the

    Original URL path: http://www.csl.com.au/research-development/clinical-trials.htm?currentPage=2 (2014-01-05)
    Open archived version from archive


  • CSL Limited and their involvement in clinical trials.
    humans it is first tested extensively in the laboratory and in animals Clinical trials are carefully supervised monitored and documented The applicable regulatory authority must grant approval to conduct testing in humans and clinical trials are overseen by an independent review body How are clinical trials conducted CSL conducts clinical trials in accordance with the current Guideline for Good Clinical Practice GCP of the International Conference on Harmonisation ICH GCP is an international ethical and scientific quality standard for designing conducting and reporting studies that involve the participation of human subjects Compliance with this standard provides public assurance that the rights safety and well being of study subjects are protected and that the clinical trial data are credible Compliance with this standard also ensures that CSL conducts clinical trials consistent with the principles that have originated in the Declaration of Helsinki Current Studies All Bleeding Disorders Critical Care Immunoglobulins Pulmonary Therapeutic Proteins Vaccines Wound Healing Condition Additional Trial Information Chronic Inflammatory Demyelinating Polyneuropathy Chronic Inflammatory Demyelinating Polyneuropathy CIDP and Treatment With Subcutaneous Immunoglobulin IgPro20 Learn More Immune Thrombocytopenic Purpura A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura ITP Learn More Hereditary Angioedema Types I and II A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 esterase Inhibitor in the Prevention of Hereditary Angioedema Learn More Surgical Blood Loss Postoperative Blood Loss Study of Fibrinogen Concentrate Human FCH to Control Bleeding During Complex Cardiovascular Surgery REPLACE Learn More Von Willebrand Disease Extension Study of Biostate in Subjects with Von Willebrand Disease Learn More Page 3 of 3 First Previous Trial Phases Following a positive outcome in preclinical testing the sponsoring organisation usually a drug manufacturer will seek approval to conduct clinical trials Once approval has been granted the sponsor will usually complete

    Original URL path: http://www.csl.com.au/research-development/clinical-trials.htm?currentPage=3 (2014-01-05)
    Open archived version from archive

  • CSL Announces Changes to the Board
    Biotech industry in the 1970s and 1980s He returned to Australia to become Executive Director of the Garvan Institute of Medical Research a position that he will be stepping down from at the end of 2011 and developed it as one of Australia s premier Medical Institutes Professor Shine was formerly Chairman of the National Health and Medical Research Council and a member of the Prime Minister s Science Engineering and Innovation Council In November 2010 he was awarded the Prime Minister s Prize for Science Professor Shine has extensive Board and governance experience and is well placed to guide CSL s strategic future Miss Alexander has been a Director of the Company since July 1991 and has been Chairman since October 2006 Prior to becoming the Chairman of CSL she was the Chairman of CSL s Audit and Risk Committee Miss Alexander played a key role in CSL s highly successful public listing and has been a constant champion of the Company s international expansion plans Her financial leadership and strong commitment to corporate governance has helped transform CSL from a domestic biologics manufacturer to a global speciality biopharmaceutical company Mr Simpson has been a director of the Company since September 2006 and has served as a member and Chairman of both the Company s Audit and Risk Management Committee and the Human Resources and Remuneration Committee CSL s Chairman elect Professor John Shine said I am very proud to be taking over as Chairman from Elizabeth after the Annual General Meeting She has made an extraordinary contribution to CSL over many years and leaves the Company well positioned for the future I would also like to recognise and thank David for his commitment and contribution during his time as a Director CSL today also announced that Mr Bruce

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853231/news/1255927066426/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Appoints New Director
    Meeting Five Year Summary R D and Operational Briefings Corporate Profile Dividends Event Calendar Shareholder Information Corporate Responsibility Careers Newsroom Contact CSL Home Investors CSL Appoints New Director CSL Appoints New Director Melbourne Australia 16 02 2011 CSL Limited ASX CSL today announced that Ms Christine O Reilly has been appointed a Director of the Company effective from 16 February 2011 Ms O Reilly is currently Co Head of Unlisted Infrastructure Investments at Colonial First State Global Asset Management a position that she has held since July 2007 In this capacity she is a director of the Anglian Water Group UK and Electricity North West UK Prior to her position with Colonial First State Global Asset Management she was the Chief Executive Officer of the GasNet Australia Group from October 2001 until December 2006 Ms O Reilly holds a Bachelor of Business and qualified as a chartered accountant She is presently a Director of Care Australia CSL s Chairman Miss Elizabeth Alexander said I am delighted that Christine has accepted the appointment to the CSL Board and am certain that with her considerable wealth of professional experience and strong financial background she will be a valuable contributor to the CSL

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853231/news/1255925861380/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Results Briefing
    Businesses Our Products Research and Development Business Development Investors Financial Reports Results Briefing Annual General Meeting Five Year Summary R D and Operational Briefings Corporate Profile Dividends Event Calendar Shareholder Information Corporate Responsibility Careers Newsroom Contact CSL Home Investors Results Briefing Full Year Results for 2008 Full Year Results for 2008 Melbourne Australia 13 08 2008 CSL Limited today announced its operating results for the full year ended 30 June

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650188/news/1218118041988/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Results Briefing
    and Development Business Development Investors Financial Reports Results Briefing Annual General Meeting Five Year Summary R D and Operational Briefings Corporate Profile Dividends Event Calendar Shareholder Information Corporate Responsibility Careers Newsroom Contact CSL Home Investors Results Briefing CSL Half Year Results Announcement for 2007 08 CSL Half Year Results Announcement for 2007 08 Melbourne Australia 20 02 2008 CSL Limited today announced its first half result for period ended 31

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650188/news/1199979298939/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Results Briefing
    Businesses Our Products Research and Development Business Development Investors Financial Reports Results Briefing Annual General Meeting Five Year Summary R D and Operational Briefings Corporate Profile Dividends Event Calendar Shareholder Information Corporate Responsibility Careers Newsroom Contact CSL Home Investors Results Briefing Full Year Results for 2007 Full Year Results for 2007 Melbourne Australia 22 08 2007 CSL Limited today announced its operating result for the full year ended 30 June

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650188/news/1196562739593/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Unsubscribe
    Germany Italy Japan Mexico Netherlands Nordic Spain Switzerland UK USA CSL Plasma US CSL Plasma Germany About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL Home Unsubscribe Unsubscribe to News Alerts

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1199979026050/page/1199979025980/Unsubscribe.htm (2014-01-05)
    Open archived version from archive